Royal News :
The Royal House Of Maharaja Adinda Aranan under the Royal Order Of Maharaja Adinda Aranan of Sulu appointed The Leading Italian Scientist, His Most Excellency Datu Laksamana Di Raja Prof. Dr. Giulio Filippo Tarro as the Grand Commander Of The Royal Order.
BIOGRAPHY
BIOGRAPHY
Italian nationality
Date of birth 09/07/1938 - MESSINA
WORKING EXPERIENCE
• Dates (from - to)
• Name and address of employer
• Type of business or sector
• Kind of employment
• Main duties and responsibilities of medical pathology Assistant
University of Naples from 02/01/1964 to 05/31/1966.
- Assistant of the Division of Virology and research for cancer at The
Children's Hospital Research Foundation in Cincinnati Ohio from 09/01/1965 to
30/06/1968
- Pediatric research professor in the Division of Virology and research
for cancer at The Children's Hospital Research Foundation in Cincinnati Ohio
from 23/11/1968 to 09/30/1969
- The CNR National Research Center from 01-01-1966 to 01-01-1975
- Oncology Professor of Virology at the Faculty of Medicine and Surgery
of the 'University of Naples from 24/01/1972 to 31/10/1985
- Professor of Microbiology and Immunology applied to Nephrology at the
school of specialization in Medical Nephrology, Faculty of Medicine and Surgery
of the 'University of Naples from 1972 to 2006
- Project Director National Cancer Institute from 09.04.1971 to
'08/04/1975
- Assistant Professor of Public Health Senior Services NCI Frederick
Cancer Center, Maryland USA from 02/13/1973 to 31/05/1973
- Primary virologist at the 'Cotugno Hospital (NA) from 01/06/1973 to
07/31/2006
- E 'was President from 1998 to 2007 of the Ethics Committee of the A O
"D. Cotugno "
- Member of the Academic Senate from 1990 Univ. Constantine of
Providence, Rhode Island, and since 1994 the Univ. Pro Deo in New York
- Honorary Academic of the University Sancti Cyrilli of Malta since
2001
- Honorary Rector of the University since 2003 Roger II of the State of
Florida in the USA,
- President of the consortium of the Campania Region "Centro
Campano Technology and Environment (CCTA) from 02/03/2004 to date
- Director of the Department of Diagnostic Services at the Cotugno
Hospital (NA) from 13-02-2003 to 12-02-2006
-Primario Emeritus of 'A.O. "D. Cotugno "by resolution # 525,
23-11-2006
- Adjunct Professor of the Department of Biology at Temple University
in Philadelphia (USA) dall'1-4-2007 today
- President of the Commission on Biotechnology of Virosfera, WABT
UNESCO, Paris from 01.02.2007.
- Life President (DPR. 03/01/78) Foundation T. & L. de Beaumont
Bonelli, for Research on Cancer, an organization with legal personality
recognized by the President of the Republic with Presidential Decree of
03/01/78.
- Chairman of the Scientific Technical Committee of the
Inter-University Consortium Higher Education "Alberto Moravia" from
02-10-2008
EDUCATION AND TRAINING
• Dates (from - to)
• Name and type of organization providing education and training
• Principal subjects / occupational skills covered
• Qualification
• Level in national classification (if appropriate) Classical High
School Diploma High School Maurolico Messina
Degree in Medicine and Surgery, mark: 110/110 cum laude, in 1962 at the
'University of Naples, Faculty of Medicine and Surgery.
Degree in Medicine H.C. Pro Deo University, Albany, New York 1989
graduate H.C. in Immunology, Academy of St. Theodora in New York in 1991, he
graduating H.C. in Bioethics, Constantinian University of Cranston, Rhode
Island (USA) 1996 Specialization in Nervous and Mental Diseases votes: 70/70
cum laude at the 'University of Naples in 1968 studies, lecturer in Virology,
Ministry of Education in 1971 in Rome.
Master of Science in Biomedical Technologies, A.S.A.M. University, Rome
2008
PERSONAL SKILLS
Acquired in the course of life and career
but not necessarily
by formal certificates and diplomas.
The best-known studies have shown the association of herpesvirus with
some human cancers. In '79 isolated respiratory syncytial virus in children
with during the outbreak of the "dark evil" of Naples. It is
currently involved in separating tumor antigens and identify their value in the
diagnosis and immunotherapy. Experience gained in the management of services of
public interest at the A. Cotugno Hospital and the monads, during the joining
of the two hospitals, led the projects finalized with regard to diagnostic and
therapeutic aspects, in the context of recurrent outbreaks of the Campania
Region from cholera to AIDS and hepatitis more recently the SARS and avian
influenza; Finally, he was able to train and qualify large staff which in turn
has also directed and organized not only in the context of 'A. O. Cotugno, but
also other health care facilities, with management responsibilities in Italy
and abroad.
FIRST LANGUAGE
OTHER LANGUAGES knows perfectly the 'English (five-year stay in the
US), also knows the French report and interviews, knows well the German report
to the Congress Hall in Berlin and writings as curriculum, also he knows
Spanish report in Madrid more see curriculum, moderately knows the Russian
frequency association Italy-USSR and belonging to the academies of Russia and
of 'Ukraine as curriculum.
Social skills and competences
Living and working with other people, in multicultural environments, in
positions where communication is important and situations where teamwork is
essential (eg. Culture and sports), etc. In the context of all the experiences
of the above direction it was in charge of organizing the training and
qualifications of the personnel directly; Especially highlights the delicate
role in qualifying the personnel chosen for the establishment of the Department
of Virology at the Cotugno Hospital; same effort was made to organize and train
staff in the field of studies carried out for the electron microscope.
As part of President of the Scientific Technical Committee of the
Inter-university higher education "Alberto Moravia Consortium" is
focusing on the choice made by the competent bodies in the education sector,
the tutoring and the right to education (see Communication appointment of the
Consortium).
ORGANIZATIONAL SKILLS
Eg. coordination and administration of people, projects and budgets; at
work, in voluntary work (eg. culture and sports) and at home, etc. As a
professor of "Virology Oncology" of the Faculty of Medicine of the
University of Naples until 1985 he was responsible for organizing the first
chair of virology oncology in Italy with all its structuring processes
personally guided in this role.
E 'was also responsible for personnel pertaining to the hospital,
fellows and staff sponsored by private and public entities seconded to the
hospital corporation. In taking responsibility for the company's goal of a
financial nature it led the passage of virology laboratories as local activities
at the regional and then national and international reference center for the
purposes of virology discovering the "dark evil of Naples"
(respiratory viruses sincinziale) with budgets of the Ministry region of
research and health.
In the quality of the National Cancer Institute project director (USA)
between 1971-75 organized by the Laboratory of Virology at the Cotugno Hospital
abutting to a Fund of the South Bank, the necessary equipment, personnel and
the structuring of the division first as a research association that used the
local hospital (1971-73) and later (1973-75) as the Diagnostic Department of
New institution as part of the Ente Cotugno hospital; in this period he has
been conducting research and has been involved in the financing of the same,
starting as a forerunner of the hospital's virology of infectious diseases and
serving as the primary conducting research and diagnostics with the hospital
staff and volunteers. As part of the experience of the direction of T. & L.
de Beaumont Bonelli Foundation for Research on Cancer she has been able to
organize international conferences with the participation of the first Nobel or
precursors of diseases that bear their name and then lead to administrative or
financial budgets from moral entity institution today directing technical /
administrative staff and research; for the same Foundation has proceeded since
1978 the economic and administrative management of the relevant real estate
assets of the same, solving with the help of professionals in charge also
delicate legal questions.
TECHNICAL SKILLS
With computers, specific kinds of equipment, machinery, etc. 1)
"Antigenic regions of Tumor Liberated Particles (TLP) complexes and
antibodies". Priority date (s): IT July 7, 1992. Europe: Patent No.
EP649433 granted on November 19, 1997 and validated in the Following countries:
Austria, Belgium, Denmark, France, Germany, Ireland, Nethelands, Portugal,
Spain, Sweden , Switzerland, United Kingdom. Eurasia & Asia Australia:
Patent No. 680,198, granted on 13/11/97; Russian Federation: Patent No.
2141969, granted on 4/21/99; South Korea: Patent No. 237250 granted on
10/10/99. US, Canada, Mexico and Brazil United States: 1) Patent No. 5,759,792,
granted on 06/02/98; 2) Patent No. 5,747,643, granted on 05/05/98; 3) Patent
No. 5,877,294, granted on 02/03/99; Canada: Patent No. 2139518, ( "Notice
of Allowance" dated 01/10/2003). 2) "Pharmaceutical compositions
comprendendo natural human interferon" Priority dates: 28.02.1996,
14.06.1996) Patents Issued Europe European Patent No. 0,886,527, granted on
9/12/01: Austria, Belgium, Denmark, France, Germany, Greece, Ireland,
Liechtenstein, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland,
United Kingdom. Other countries: Australia: Patent No. 722,987, granted on
November 30, 2000; Eurasia (Armenia, Azerbaijan, Belarrus, Kyrgyzstan,
Kazakhstan, Maldava, Tajikistan, Turkmenistan): Patent No. 001,147, recently
granted (the granting date is not yet available). Georgia: Patent No. 2489,
granted on July 25.2001; Italy: 1) Patent No. 1,283,945, granted on May 7, 1998;
2) Patent No. 1,284,852, granted on May 22, 1998. North Korea: Patent No.
33639, granted on December 24, 1999; Russian Federation: Patent No. 001,147,
recently granted (see "Eurasia"); 3) "Urogenital carcinoma TLP
complex peptides and antibodies thereof". Priority date (s): IT October
10, 1996 Europe: Patent No. EP851872 granted on April 18, 2001 and validated in
the Following countries: Austria, Belgium, Denmark, France, Germany, Greece,
Ireland, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom. 4)
"Immunogenetic TLP composition" Priority dates (s): IT July 10, 1996.
Europe: Patent No. EP938329 granted on May 29, 2002 and validated in the
Following: Austria, Belgium, Denmark, France, Germany, Ireland, Netherlands ,
Portugal, Spain, Sweden, Switzerland, United Kingdom. Other countries:
Australia: Patent No. 725,218, granted on January 25, 2001. Russian Federation:
Patent Applications No. 2,192,274, granted on November 10, 2002. 5)
"Sticking plaster for controlled release of natural interferon"
Priority date (s) : see PCT application. International Patent Application No.
PTC / EP98 / 03809, filed on June 22.1998, Has Been extended in the Following
countries: Australia, Canada, China, Europe, Japan, Mexico, New Zealand,
Norway, U.S.A. The International Preliminary Examination Report, issued at the
end of the PCT procedure, has Expressed a favorable opinion with regard to
novelty, inventiveness and industrial applicability. Austria: Patent No.
84396/98 Has Been allowed and the Corresponding Patent issued shortly. New
Zealand Patent No. 509029 Has Been allowed and the Corresponding Patent issued
shortly. 6) "Transdermal pathch and tropical compositions comprendendo
propylnorapomorhine". Priority date (s): IT July 17, 1998. International Patent
Application No. PTC / IE99 / 00066, filed on July 15.1999, Has Been extended in
the Following countries: Australia, Canada, China, Europe, Japan, Mexico, New
Zealand, Norway, USA The International Preliminary Examination Report, issued
at the end of the PCT procedure, has acknowledged the novelty of the claims
Japan: Patent Applications No. 2000-559833, filed on January 15, 2001. Mexico:
Patent No. 000527, filed on January 15 , 2001. Norway: Patent Applications No.
20010248, filed on January 15, 2001. 7) "Use of rubidium and in Particular
rubidium chloride as an antimaniac agent and stabilizer for mood swings."
Priority date (s): IE April 19, 1999. International Patent Application No. PTC
/ IE00 / 0004, filed on April 17.2000, Has Been extended, Within the terms Foreseen
by the international conventions, in the Following countries: Canada, China,
Europe, Japan, Mexico, New Zealand, Norway, USA The International Preliminary
Examination Report, issued at the end of the PCT procedure, has Expressed a
favorable opinion with regard to novelty, inventiveness and industrial
applicability. 8) "TLP Peptides and DNA-sequences coding the same".
Priority date (s): IT February 25, 2000. The International Patent Application
No. PTC / E001 / 01857, filed on Februry 20.2001, Has Been extended, Within the
terms Foreseen by the in ternational conventions, in the Following countries:
Australia, Brazil, Canada, China, Japan, North Korea, Russian Federation, South
Korea, USA Europe, designating: Austria, Belgium, Cyprus, Denmark, Finland,
France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands,
Portugal, Spain, Sweden, Switzerland Liechteinstein, Turkey, United Kingdom.
The International Preliminary Examination Has Been Concluded (IPER issued on
May 21, 2002) with a positive opinion regard to novelty, inventiveness and
industrial applicability of the claims Concerning the cDNA of TLP, the peptide
coded by the same and the relevant pharmaceutical compositions. 9)
"Diphenyl ketoaldehyde derivatives with anti-HIV activity." Priority
date (s): IT March 24, 2000. The International Patent Application No. PTC /
EP01 / 03343, filed on March 23.2001, Has Been extended, Within the terms
Foreseen by the international conventions, in the Following countries:
Australia , Brazil, Canada, China, Japan, Mexico, New Zealand, Norway, Russian
Federation, South Africa, USA Europe, designating the Following countries:
Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland,
Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland /
Liechteinstein, Turkey, United Kingdom. The International Preliminary
Examination Report, issued at the end of the PCT procedure, has acknowwledged
the novelty of the invention. 10) "Compounds with anti-rhinovirus activity"
.Italy: The Patent Application filed on June 9.2000 under No. MI2000A001288,
has not Been extended. 11) "Slow release" pharmaceutical compositions
comprendendo lithium carbonate. Priority Date (s): IT August 6, 2001.
Priority: IT / 10.08.00 / ITA MI001868 + IT / 14.O2.01 / MI000299.
Designated states: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU,
MC, NL, PT, SE, TR. The International Patent Application No. PTC / EP01 /
09054, filed on August 6.2001, and extended, Within the term Foreseen by the international
conventions, in the Following countries: Europe, designating the Following
countries: Austria, Belgium, Cyprus, Denmark , Finland, France, Germany,
Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain,
Sweden, Switzerland / Liechteinstein, Turkey, United Kingdom, and moreover in:
"Euroasiatic Area", designating the Following countries: Armenia,
Azerbaijan, Belarrus, Russian Federation, Kyrgyzstan, Kazakhstan, Maldava,
Tajikistan, Turkmenistan. Australia, Brazil, Canada, China, Japan, U.S.A. On
October 2, 2002, the IPER (International Preliminary Examination Report), has
Expressly acknowledged novelty, inventiveness and industrial applicability of
all the five claims. 12) "TLP Antigen and diagnostic applications thereof".
Priority Date (s): EN, June 29,2001.The International Patent Application No.
PTC / EP02 / 07020, filed on June 25, 2002 Has Been published on January 9,
2003 under No. WO03 / 002591.The international preliminary Within examination
Concluded October 29, 2003, while the national / regional started Within
December 29, 2003. 13) "Fusion Proteins containing TLP peptides".
Priority Date (s): IT, November 30, 2001. The International Patent
Application No. PTC / EP02 / 13470 Has Been Filed on November 29, 2002. 14)
"Compounds with anti-rhinovirus activity". The Italian Patent
Application (No. MI2002A000966), filed on May 8, 2002 extended Within the
priority year as PTC application. Date (s): December 13, 2004. Application No
.: No./Patent 03727431.3-2123-EP0304673. Date of filing: May 5, 2003. Priority:
IT / 08.05.02 / ITA MI20020966. Designated states: AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE , SI, SK,
TR. 15) "Pharmaceutical composition containing the association LevodopaCarbidopa".
Italian Application filed on April 18, 2003. 16) "Pharmaceutical
compositions containing interferon f or the treatment of Human Papilloma Virus
Infections". Italian Application filed on April 18, 2003
ARTISTIC SKILLS
Music, writing, design, etc. Selected publications (over 500 articles
in total)
Recherches sur le mechanisme d'action d'un groupe de medicaments
antiviral activité (produits du chetoaldéhydiques diphényle et leur dérivés):
Facteurs here interferent sur leur activité protectrice in vivo. (With F.
Magrassi, Altucci P. et al.). III Internat. Cong. Of Chemotherapy - Stutgart,
July 1963. Proceedings, p. 783 (1964). Studies on the mechanism of antiviral
activity of ketoaldehyde derivates of biphenyl. (With F. Magrassi, Altucci P.
et al.) International "Symposium on non-specific resistance to virus
infection, Interferon and viral chemotherapy" Smolenice, September 1964.
Chemotherapia 9, 341, 1964. Studies on the mechanism of antiviral activity of
biphenyl ketoaldeydes. (With F. Magrassi, p. Altucci et al.), Proceedings of
the Fourth Congress of the Hungarian Association of Microbiologists Akadémiai
Kiado Budapest 1964, p. 11. Properties of an avirulent influenza A virus
variant derived from drug treated mice infected with PR8 virus. (With Magrassi
F., et al.) In "Antimicrobial Agent and Chemotherapy", page 605
(1965). Properties of an avirulent influenza A virus variant derived from drug
treated mice infected with PR8 virus. (With Magrassi F., et al.) Arch. Ges. Virusforsch,
18, 422, 1966. Effect of Streptovitacin A on replication of RNA viruses
(poliovirus). Proc. Soc. Exp. Biol. Med. 126, 535. 1967. Specific Virus,
Labile, Nonvirion Herpes Virus Antigen in Infected Cells. (With A. B. Sabin)
Proc. Natl. Acad. Sci. U.S. 65, 753, 1970. Increase in Preexisting Cellular
Antigen Combining Groups at Different Times after Infection with Different
Viruses. (With A. Sabin) Proc. Natl. Acad. Sci. U.S. 67, 731, 1970. Studies on
the mechanism of antiviral activity of Ketoaldheide derivates of bifhenil.
(With Magrassi F. et al.) Rev. Roum. of inframicobiol. 5, 275, 1968. Effect of
two methisazone derivatives on herpes simplex virus replication. (With P.
Mastroeni). VII Intern. Congress of Chemoterapy, August 1971 Avicenum, Czechoslovak
Medical Press, Prague, p. 273. Soluble Membrane Antigens of Lip and Cervical
carcinomas: Reactivity with Antigens Antibody for Herpesvirus Nonvirion. (With
A. C. Hollinshead) Science 179, 698, 1973. apperance in trypsinized Normal
Cells of Reactivity Presumably with Antibody Specific for Malignant Cells.
Proc. Nat Acad. Sci. USA 70, 325, 1973. Nonvirion Antigens Produced by Herpes
Simplex Viruses I and 2. (with A. B. Sabin) Proc. Nat. Acad. Sci. USA, 70,
1032, 1973. Herpes Simplex and Herpes Virus in Genitalis Some Etiology of Human
Cancers. (With A. B. Sabin) Proc. Nat. Acad. Sci. USA, A70, 3225, 1973. Studies
of Tumor-specific and Herpes Virus Not virion Antigens. (With A. Hollinshead et
al.) Cancer Res. 34, 1122, 1974. Characterization of herpesvirus not virion
antigens: relation to squamous cell arcinomas. (With A. Hollinshead, W. Rawls
and P. Chretien) In Kurstak and E. Morriset R. (ed) "Viral
Immunodiagnosis", Academic Press, New York, 1974. Soluble Membrane
Antigens of Lip and Cervical carcinomas: Reactivity with Antigens Antibody for
Herpesvirus Nonvirion. (With A. C. Hollinshead) Year Book of Cancer 1974.
Analysis and Description of Procedures Used in the Study of the Relationship of
Herpes Simplex "Nonvirion" Antigens to Certain Cancers. In C. de Thé,
MA Epstein, H. zur Hansen (ed.) "Oncogenesis and Herpesviruses" IARC,
Lyon, 1975. Preliminary studies of nonvirion antigens Associated with Herpes
Simplex Virus 1 and 2 (HSV-1 HSV-2) ( with Accini R. et al.) Bull. Inst.
Sieroter. Milan 55, 120 1976 Herpes Simplex Virus nuclear non-virion antigens
detected by immunofluorescence anticomplement (with C. Giordano et al.) Cancer
62 (6) 609, 1976. Herpes Simplex virus tumor associated antigens in cancer
patients (with Joy M. et al.) cancer 62 (6) 615, 1976. Cell-mediated immunity
to herpes simplex virus types 1 and 2 antigens in leucoplakia and cancer in
man. (With EJ Shillitoe, T. Lehner) Oncology 33, 192, 1976. Detection of early
antigens in the nuclei of cells infected by cytomegalovirus, herpes simplex
type 1 and 2 by anticomplement immunofluorescence assay and blocking to
Demonstrate Their specifity. (With G. Giraldo , E. Beth, U. Hammerling, FM
Kourilsky) Int. J. Cancer 19, 17, 1977. Enzyme Linked Immunosorbent Assay for
Herpes Simplex Virus Tumor-Associated Antigen. (With R. Bisaccia et al.) Cancer
45, 938, 1980. An Immune Enzymatic Assay for Purified Tumor Associated Antigen
of Herpes Simplex Virus. (In coll.) Cellular and Molecular Biology 25, 329,
1980. Purification of Herpes Virus Tumor Associated Antigen from Human Kidney
cancer. (With R. Bisaccia et al.) Cancer 46, 1594, 1980. Foreword of the
proceedings of the First International Congress of Viral Oncology The role of
Virus in Human Cancer, vol. 1 Elsevier, North Holland, 1980. Herpes Simplex Virus
Tumor Associated Antigen (HSV-TAA) Detected by the Enzyme-linked immunosorbent
assay (ELISA). in The Role of Viruses in Human Cancer, vol. 1 Giraldo and Beth
Publishers, Elsevier North Holland inc., P. 108, 1980. The TAF tests: a new
method for the diagnosis of certain cancers. Medical journal of Italian
Switzerland 45, 245, 1980 Monoclonal Antibodies to Herpes Simplex Virus Tumor
Associated Antigen. (With A. Karpas and T. Wheeler) International Workshop on
Herpesviruses Soc. Aesculapius Edizioni, Bologna 1981, p. 232. Circulating
Immunocomplexes (CIC) in Sera of Patients with Herpes Simplex Virus (HSV) -
Associated carcinomas. (In coll.) International Workshop on Herpesviruses Soc.
Aesculapius Edizioni, Bologna 1981, p. 236. traitment de la herpetique avec le
metiseprinol. Aspect clinique et histologique (with G. Gorgone, Cavallaro N.,
S. ladder, Carnazza S., M. Ricci, G. Gala Trinchera, Cordaro S.) Bull. Soc.
Belge Ophtal. 192113-123 1981 Perspectives and limits of an immunoenzymatic
assay (ELISA) for Herpes Simplex Virus (HSV) Tumor-Associated Antigen (TAA).
Cancer Detection and Prevenction 4, 47, 1981. An immunoenzymatic assay for
herpes simplex virus tumor associated antigen in gynecological oncology (with
G. Magli, C. Scimone, Flaminio G., G. D'Alessandro, Mascolo A., R. Magli
Saladin I.) Eur. J. Gynaec. Oncol. 1982 ISSN: 0392.2936.III.2 Further Studies
on an Immunoenzymatic Assay for Heres Simplex Virus-Tumor Associated Antigen.
(In coll.) Clin. Immunol. Immunopath .. 25, 126, 1982. Human tumor antigens
inducing delayed hypersensitivity in vivo and in vitro mitogenic activity.
(With A. Pederzini et al.) Oncology 40, 248, 1983. As above Immunomodulation
amd Therapy in Cancer (with Pedercini A. et al.) And. H.H. Fuderberg, P.
Pontiggia, C. ogler, Acta Medica edit. Congress 1983, p. 307 Virological
Investigation of Young Children with Acute Respiratory yndrome Synctyal
Associated with Respiratory Virus (RSV). (In coll.) In Medical Virology II,
Editor L.M. La Maza, E.M .. Peterson Elseiver Biomedical, 1983, p. 402.
Quantitative Determination of Human CMV IgG Antibodies by solid phase enzyme
immunoassay: comparison with CF test. (In coll.) In Medical Virology II -
Editor L.M. La Maza, E.M .. Peterson Elseiver Biomedical, 1983, p.392.
Correlation between immune complexes and Herpes Simplex Virus (HSV) Tumor
Associated Antigen (TAA) in Human Cancer Sera. (With others) Cellular and
molecular biology 29, 394, 1983. The role of herpes simplex virus in the
neoplastic pathologies and diagnostic markers. J. Exp. Clin. Cancer Res. 4 (2),
213, 1985. Serological and Virological Investigations of Young Children with
Acute respiratory Syndrome Associated with Respiratory Syncytial Virus.
Diagnostic Microbiology and Infection Disease 3 (1), 81,
1985. The pathogenesis of malignant tumors X Dies Italico-Iugoslavici Medicinae
intended, Lugnano, 1985 Screening hemodialysis patients for infection with
human immune deficiency virus (HIV). Journal of Infection 14, 1987, p. 229.
Absence of risk of human immunodeficiency virus (HIV) infection in recipients
of hepatitis B vaccine. Eur. J. Epidem. 3, 1987, p. 323. Viruses and
immunodeficiences. "Regulation of Mammalian Cell Growth", Capri 27-9
/ 10.2.87, p. VIR 9, Ciba-Geigy. Monoclonal antibody for tumor associated antigens
induced by Herpes Simplex Virus. Advances in Management of Malignancies,
Proceedings of an international congress, Ascoli Piceno, 3 / 06.05.1988.
Laboratory methods for diagnosis of AIDS. Significance of sierological markers
(with others) Italian Journal of Clinical Pathology 3 (6) 1988, p. 393 Search
for tumor antigens to be used for active specific immunotherapy. Abstract book
of the 2nd Internationl Congress "Advance in Management of Malignannces,
Ascoli Piceno 28 / 5-1 / 6/1990 p. 36 Histochemistry and Immunolohistochemistry
in the diagnosis of prostatic carcinoma (with others) Abstract book of the 2nd
International Congress "Advances in Management of Malignancies",
Ascoli Pisceno, 28 / 5-1 / 6-1990, p. 93 Epidemiological, serological, evolution
aspects of HIV infection and related malignancies Within Naples area (Jan '86
-Dec. '89). Abstract book of the 2nd International Congress "Advances in
Management of Malignancies", Ascoli Pisceno, 28 / 5-1 / 6-1990, p. 19.
Methoden in vitro als bei tierversuchersatz immunologishen studien. in AA.VV.
"Artze fur Die Abschaffung der Tierversuche" Bern 1990, p. 77
(German); p. 167 (French); p. 255 (Italian). Neutralization tests and antibody
titers in AIDS (with Valguarmera G. et al.) European Clinical 30 (2) June 1991
HIV Infection and Serological Response (with C. Esposito et al.) Clinical
Biochemistry 15, 1991Seroepidemiologic patten of HCV infection in Campania
During the first six months 1992 (with C. Esposito et al ..) Abstract, Journal
of Hepatology supplement 1 to vol 17, 5028, 1992 Screening of HTLV-1 infection
drug addicts from Campania region. Advances in Management of Malignancies Pisa,
6 / 10-12, 1993, p.33 BIOS Ed. Lung cancer histopatholocic approaches for a
prognostic valuation (with others) Advances in Management of Malignancies Pisa
6 / 10- 12/1995 p. 237 and BIOS. Antigenic regions of tumor liberated protein
complexes and antibodies against the same (with. Marshak DR et al) In Third
International Congress. Advances in Management of Malignancies. Pisa, Italy
6/10 December 1993 Biomed & Pharmacother 47: 237Vom Anthropozentrismus zur
Antivisektion: Tierschtz heute und Jurassic Park. Proceedings of International
Medical Congress, Lugano 20/11/93. LIMAV, p. 195 Ed. ASTRA / AG STG March 1995.
Passive immunotherapy in AIDS patients Italian Journal of Medical Research and
Chirurigiche Year III vol. 3 n. 3 September 1995 p. 11 Anti-TLP antibodies in
lung cancer patients. (With C. Esposito et al.) Internal Medicine Clinical
Laboratory 5191-194, 1997.The Genome Project: Ethical implications in oncology.
In: Internal Medicine Clinical Laboratory 6 67-72, 1998 Immunoistochemical
characterization of tumor liberated particles (TLP) expression pattern in lung
cancer. (With A. Jordan et al.) Anticancer Res 18: 2365-2370, 1998 Los derechos
de los animales Actas Congreso medico international LIMAV Madrid Mayo 1997 ARTA
STG enero 1998 Effect of Bergarital on virus replication Italian research
journal Medical and Surgical Publishing Doctor's year VI n. 2/4 April /
December 1998 Neoangiogenesis and prognosis in lung Cencer (with A. Perna et
al.) Internal Medicine Clinical Laboratory 7111-113, 1999 Tumor liberated
protein (TLP). Its potential for diagnosis and therapy. Anticancer Res 19:
1755-1758, 1999 Immunity Herpes Simplex Virus (HSV) (with others) Proceedings
of International Workshop on Viruses Immunities and Diseases, Naples, October
1999 AIMS and Perspectives for Liberated Tumor Protein (TLP) proceding of the
Joint International Cancer Conference "New Dimension in Cancer Biology
Therapy on" Edition H. Ozer, K. Khalili, GC Jordanian As above Riv It Ric.
Med Chir 7: 43-46 1999 Vom freigesetze Tumor Protein: Neuer Wendepunkt fur
Diagnose und Therapie von ohne Notwendigkeit Tierversuchen. Humanmedizin ohne
Tierversuche: Die Artze haben das Wort. Berlin Mai 1999 ASTRA - AG STG pages.
67-74 Overview of the Lung Tumor Liberated Protein (TLP): Characterization of
Genetic Immunologic Profile Internal Medicine Clinical and Laboratory 8 33-38,
2000 Immunochemical evaluation of endothelal damage by angioinvasivity. (With
Perna A, et al.) Int J. Clin Invest 9: 31-33, 2001 Production and
characterization of anti-TLP derived peptide RTNKZEASIC) monoclonal antibodies.
(With C. Esposito et al.) Int Med 9: 55-61, 2001 Characterization of a Fragment
Containing a Putative TLP Sequence DNA. Anticancer Research, 22: 2693-6, 2002
UCV genotypes and antibodies reactivity what's relations? Journal of
Hepathology Suppl. 1, Vol.30, 1999 pag.209. (With C. Esposito, F. Morelli, N.
Cuomo, A. Di Spirito) Evaluation of a new test for the determination of the HCV
genotypes JournaI of Clinical Virology, 22/2: 174, 2002 Hepatopaty and
oxidative stress: clinical study on the efficacy of the depatox Int. J. Clin.
Invest. 1: 15 -18, 2003 Determination of the polymerasis HBV gene mutation in
HBV patients treated ECA and naive. (With C. Esposito et al.) Journal of
Clinical Virology suppl.
